BiotechTube
Avocet Bio

Avocet Bio

Munich, Germany· Est.
avocet.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Avocet Bio is a private, preclinical-stage biotech developing a CRISPR/Cas13-based platform for broad-spectrum antiviral therapeutics. Founded by a team of clinician-scientists and seasoned drug developers, the company aims to create a 'plug-and-act' solution capable of rapidly addressing diverse RNA virus threats, including potential future pandemics. While still in early development, its technology platform represents a novel approach in the infectious disease space, targeting the viral RNA genome and transcripts to block proliferation. The company is pre-revenue and focused on advancing its platform technology.

Infectious Diseases

Technology Platform

Programmable CRISPR/Cas13-based platform designed to cleave and degrade the RNA genome and transcripts of any RNA virus, enabling broad-spectrum antiviral therapeutics.

Opportunities

The platform addresses the massive unmet need for rapid-response therapeutics against pandemic RNA viruses and endemic threats with poor treatment options.
Its adaptable 'plug-and-act' design could make it highly valuable for government pandemic preparedness stockpiling and partnerships with large pharma for specific virus families.

Risk Factors

Major risks include the significant scientific challenge of safe and effective in vivo delivery of the CRISPR/Cas13 system, potential immunogenicity and off-target effects, and the long, costly, and uncertain path to clinical validation.
The pandemic-focused business model may also face commercial sustainability challenges.

Competitive Landscape

The company competes in the crowded antiviral space, facing competition from traditional small-molecule and antibody developers, as well as other gene-editing and RNA-targeting platforms (e.g., using Cas9, ARCUS, or RNAi) from both academia and companies like Sherlock Biosciences, Mammoth Biosciences, and Arbutus Biopharma.

More companies in Germany →